Lees-Rolfe Garth 4
4 · Inhibikase Therapeutics, Inc. · Filed Apr 2, 2024
Insider Transaction Report
Form 4
Lees-Rolfe Garth
Chief Financial Officer
Transactions
- Award
Stock Option (right to buy)
2024-04-01+90,000→ 90,000 totalExercise: $2.16Exp: 2031-04-01→ Common Stock (90,000 underlying)
Footnotes (1)
- [F1]One-third of the options will vest and become exercisable on April 1, 2025, one-third of the options will vest and become exercisable on April 1, 2026, and one-third of the options will vest and become exercisable on April 1, 2027, in each case subject to continued employment through each such vesting date.